MRNA Moderna Inc
Company Analysis
Latest News
🔴 Moderna is trading 6% down today after upsized $2.6 billion note offering raises dilution concerns
Moderna is trading 5.59% down at $134.79 after pricing an upsized $2.6 billion private placement of convertible senior notes due 2032, raising dilution...
Moderna Secures FDA Approval for 2026 Vaccines, Targeting XFG Variant
The U.S. Food and Drug Administration (FDA) approved Moderna’s Spikevax and mNEXSPIKE vaccines on August 27, 2026. These updated formulations target the...
🔴 Moderna is trading 4.6% down today after proposing $2 billion private placement of convertible notes
Moderna is trading 4.6% down now at $142.81 after announcing a proposed $2 billion private placement of convertible senior notes due 2032. - The notes may be...
🔴 Moderna is trading 4.3% down in pre-market as investors take profits after cancer-vaccine rally
Moderna is trading 4.28% down now at $143.25 as investors continue taking profits following the extraordinary cancer-vaccine rally. - Recent coverage...
🔴 Moderna is trading 6.5% down today after profit-taking following its cancer-vaccine rally
Moderna is trading 6.5% down at $148.52 as investors continue taking profits after its extraordinary cancer-vaccine-driven rally. - Recent coverage links the...
🔴 Moderna is trading 5% down today after continued profit-taking following cancer-vaccine rally
Moderna is trading at $151.09 (-4.87%) as investors continue taking profits after its extraordinary recent rally tied to positive Phase 3 cancer-vaccine...
Moderna Upgraded by Wolfe Research, Citing Phase 3 Cancer Vaccine Success
Wolfe Research upgraded Moderna from Underperform to Peer Perform. The rating change follows a successful Phase 3 trial for intismeran, a personalized cancer...
🟢 Moderna is trading 11% up today after positive Phase 3 melanoma-vaccine results
Moderna is trading at $153.71 (+10.67%) as investors extend the sharp repricing after its August 19 Phase 3 melanoma-vaccine results with Merck showed reduced...
🟢 Moderna is trading 6% up today as investors refocus on positive melanoma vaccine results
Moderna is trading 5.67% up at $146.77 after renewed investor attention to positive Phase 3 results for its personalized melanoma vaccine. - Moderna and Merck...
🔴 Moderna is trading 7.35% down today
Moderna is trading 7.35% down at $134.47 after no new company-specific announcement was identified for August 24, 2026. • The decline follows an exceptionally...
🟢 Moderna is trading 12.41% up today after recovering from August 20’s 23.55% drop
Moderna is trading $149.86 (+12.41%) after recovering from the August 20 profit-taking decline. • The decline was 23.55%, following the prior session’s...
🟢 Moderna is trading 10.23% up today after a 23.55% fall on August 20 following profit-taking
Moderna is trading at $146.96, up 10.23%, rebounding after heavy profit-taking following its 176.97% surge on August 19. - Shares fell 23.55% to $133.32 on...
🟢 Moderna is trading 8.5% up today after a 23.55% fall on August 20
Moderna is trading at $144.62, up +8.47%, rebounding after falling 23.55% to $133.32 on August 20. - No clear new company-specific catalyst was identified for...
🟢 Moderna is trading 5% up in pre-market with no clear company-specific catalyst
Moderna is trading 5.15% up now at $140.19 after a sharp prior-session pullback, with no clear fresh company-specific catalyst for the rebound. - The Phase 3...
🔴 Moderna is trading 18% down today after profit-taking from August 19 surge
Moderna is trading at $143.77 (-17.55%) after apparent profit-taking following its August 19 surge. - Shares surged 176.97% on August 19 to $174.38. - The...
🔴 Moderna is trading 11.2% down in pre-market after apparent profit-taking following August 19's 176.97% surge
Moderna is trading 11.2% down at $154.91 after investors appeared to take profits following its 176.97% regular-session surge on August 19. - The rally...
🔴 Moderna is trading 5.5% down in after-hours trading after 176.97% regular-session surge
Moderna is trading 5.5% down at $164.77, apparently due to profit-taking after its exceptional regular-session rally. - It closed at $174.38 on August 19,...
🟢 Moderna is trading 11.26% up in after-hours trading after positive Phase 3 melanoma vaccine results
Moderna is trading at $194.02 (+11.26%) after the company and Merck reported positive Phase 3 results for their personalized mRNA melanoma vaccine. -...
Moderna's Stock Doubles on Cancer Vaccine Breakthrough — But Can a Company Burning Cash Grow Into a $50 Billion Valuation?
Shares of Moderna surged as much as 104.8% to $128.92 Wednesday after the company and partner Merck announced that their personalized mRNA cancer vaccine hit...
🟢 Moderna is trading 102.38% up today after Phase 3 melanoma trial success
Moderna is trading 102.38% up at $128.92 after its personalized mRNA cancer vaccine, developed with Merck, met the primary recurrence-free-survival endpoint in...